

# Mikkel Bring Christensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6594213/publications.pdf>

Version: 2024-02-01

114  
papers

4,609  
citations

126708

33  
h-index

114278

63  
g-index

120  
all docs

120  
docs citations

120  
times ranked

4760  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucoseâ€dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, doubleâ€blind, placeboâ€controlled, crossover clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 142-147.	2.2	4
2	Glucagon Clearance Is Preserved in Type 2 Diabetes. <i>Diabetes</i> , 2022, 71, 73-82.	0.3	6
3	Acute changes in plasma glucose increases left ventricular systolic function in insulinâ€treated patients with type 2 diabetes and controls. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1123-1131.	2.2	3
4	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. <i>Cell Reports Medicine</i> , 2022, 3, 100582.	3.3	21
5	Effects of a comprehensive medication review intervention on healthâ€related quality of life and other clinical outcomes in geriatric outpatients with polypharmacy: A pragmatic randomized clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3360-3369.	1.1	10
6	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1882-1887.	2.2	5
7	Shortâ€term mortality following tramadol poisonings in Denmark. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 131, 83-92.	1.2	5
8	Drug use in patients with short bowel syndrome and intestinal failure.. <i>Danish Medical Journal</i> , 2022, 69, .	0.5	0
9	A poison information centre can provide important assessment and guidance regarding medication errors in nursing homes: A prospective cohort study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 542-549.	1.2	0
10	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e966-e981.	1.8	22
11	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP</scp> receptor antagonist <scp>GIP</scp> (3â€30) <scp>NH<sub>2</sub></scp> on <scp>GIP</scp> actions in humans. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 68-74.	2.2	14
12	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 17-35.	2.2	27
13	Pancreatic polypeptide: A potential biomarker of glucoseâ€dependent insulinotropic polypeptide receptor activation in vivo. <i>Diabetic Medicine</i> , 2021, 38, e14592.	1.2	1
14	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. <i>European Journal of Endocrinology</i> , 2021, 185, 343-353.	1.9	12
15	Causes of discrepancies between medications listed in the national electronic prescribing system and patients' actual use of medications. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 221-231.	1.2	10
16	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998â€2018. <i>Scientific Reports</i> , 2021, 11, 13603.	1.6	8
17	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 231-243.	1.0	51
18	Effects of endogenous GIP in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2021, 185, 33-45.	1.9	21

#	ARTICLE	IF	CITATIONS
19	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. <i>Diabetologia</i> , 2021, 64, 2425-2431.	2.9	4
20	Exendin(9â€³9) <sc>NH<sub>2</sub></sc>: Recommendations for clinical use based on a systematic literature review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2419-2436.	2.2	15
21	Mechanisms in Endocrinology: The physiology of neuronostatin. <i>European Journal of Endocrinology</i> , 2021, 185, R93-R101.	1.9	0
22	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes. <i>ELife</i> , 2021, 10, .	2.8	20
23	Two-bag intravenous N-acetylcysteine, antihistamine pretreatment and high plasma paracetamol levels are associated with a lower incidence of anaphylactoid reactions to N-acetylcysteine. <i>Clinical Toxicology</i> , 2020, 58, 698-704.	0.8	9
24	GIP and the gut-bone axis â€“ Physiological, pathophysiological and potential therapeutic implications. <i>Peptides</i> , 2020, 125, 170197.	1.2	25
25	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. <i>Peptides</i> , 2020, 125, 170183.	1.2	61
26	GIPâ€™s involvement in the pathophysiology of type 2 diabetes. <i>Peptides</i> , 2020, 125, 170178.	1.2	18
27	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e502-e510.	1.8	12
28	GIPâ€™s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3â€“30)NH <sub>2</sub> . <i>Bone</i> , 2020, 130, 115079.	1.4	20
29	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. <i>Peptides</i> , 2020, 125, 170174.	1.2	27
30	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. <i>Bone</i> , 2020, 140, 115553.	1.4	25
31	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa097.	0.1	12
32	Medication-related experiences of patients with polypharmacy: a systematic review of qualitative studies. <i>BMJ Open</i> , 2020, 10, e036158.	0.8	25
33	Highâ€“Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Betaâ€“Adrenoceptor Blockade: A Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016828.	1.6	15
34	Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years. <i>Scientific Reports</i> , 2020, 10, 4095.	1.6	6
35	Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. <i>Neurochemistry International</i> , 2020, 138, 104772.	1.9	11
36	What is on the horizon for type 2 diabetes pharmacotherapy? â€“ An overview of the antidiabetic drug development pipeline. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1253-1265.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Total burden of disease in cancer patients at diagnosis—a Danish nationwide study of multimorbidity and redeemed medication. <i>British Journal of Cancer</i> , 2020, 123, 1033-1040.	2.9	17
38	Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 871-882.	0.9	10
39	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e725-e738.	1.8	37
40	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 588-596.	4.3	38
41	GIP(3-30)NH <sub>2</sub> — a tool for the study of GIP physiology. <i>Current Opinion in Pharmacology</i> , 2020, 55, 31-40.	1.7	8
42	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, .	0.3	3
43	Effect of a medicines management model on medication-related readmissions in older patients admitted to a medical acute admission unit—A randomized controlled trial. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 88-96.	0.9	21
44	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4092.	1.8	47
45	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. <i>Diabetologia</i> , 2019, 62, 665-675.	2.9	81
46	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2953-2960.	1.8	41
47	THU0670—PATERNAL USE OF METHOTREXATE AND CONGENITAL MALFORMATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS. , 2019, , .		0
48	Hemodynamic Effects of Intravenous, High-Dose Lipid Emulsion With and Without Metoprolol Infusion in Healthy Volunteers: A Randomized Clinical Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1009-1017.	2.3	3
49	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. <i>Diabetes</i> , 2019, 68, 906-917.	0.3	118
50	Long term treatment with stimulant laxatives — clinical evidence for effectiveness and safety?. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 27-34.	0.6	28
51	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.3	10
52	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 288-294.	1.8	64
53	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. <i>Peptides</i> , 2018, 100, 173-181.	1.2	56
54	A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Treatment Options. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 650-659.	1.2	25

#	ARTICLE	IF	CITATIONS
55	GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. <i>Diabetologia</i> , 2018, 61, 413-423.	2.9	66
56	Important Aspects of Pharmacist-led Medication Reviews in an Acute Medical Ward. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 253-261.	1.2	9
57	Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 293-298.	1.2	10
58	Outcomes following calcium channel blocker exposures reported to a poison information center. <i>BMC Pharmacology &amp; Toxicology</i> , 2018, 19, 78.	1.0	8
59	General Practitioners'™ Barriers Toward Medication Reviews in Polymedicated Multimorbid Patients. <i>Health Services Research and Managerial Epidemiology</i> , 2018, 5, 233339281879216.	0.5	13
60	Response to Letter to the Editor: "Hemodynamic Effects of Glucagon: A Literature Review". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4480-4481.	1.8	0
61	Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00431.	1.1	30
62	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 530-536.	0.5	22
63	Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 1161-1167.	2.5	9
64	Effects of high-dose, intravenous lipid emulsion on laboratory tests in humans: a randomized, placebo-controlled, double-blind, clinical crossover trial. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 2047-2057.	1.4	3
65	Hemodynamic Effects of Glucagon: A Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1804-1812.	1.8	43
66	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. <i>Diabetes</i> , 2018, 67, 145-OR.	0.3	3
67	Mono- and Co-Activation of the GIP and GLP-1 Receptors Inhibits Bone Resorption. <i>Diabetes</i> , 2018, 67, .	0.3	4
68	Topical pharmacological treatment of hemorrhoids during pregnancy and congenital malformations - a nation-wide cohort study. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-5-16.	0.0	0
69	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. <i>Clinical Pharmacokinetics</i> , 2017, 56, 719-731.	1.6	18
70	Quality of care for people with multimorbidity "a case series. <i>BMC Health Services Research</i> , 2017, 17, 745.	0.9	22
71	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166125.	1.1	188
72	Searching for the physiological role of glucose-dependent insulinotropic polypeptide. <i>Journal of Diabetes Investigation</i> , 2016, 7, 8-12.	1.1	30

#	ARTICLE	IF	CITATIONS
73	Species-specific action of (Pro3)GIP " a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. British Journal of Pharmacology, 2016, 173, 27-38.	2.7	86
74	N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor. British Journal of Pharmacology, 2016, 173, 826-838.	2.7	72
75	Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. British Journal of Clinical Pharmacology, 2016, 82, 1291-1302.	1.1	39
76	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4377-4384.	1.8	12
77	Medication review in hospitalised patients to reduce morbidity and mortality. The Cochrane Library, 2016, 2016, CD008986.	1.5	179
78	Effects of glucose-dependent insulinotropic polypeptide on glucagon. Cardiovascular Endocrinology, 2016, 5, 75-81.	0.8	1
79	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2076-2083.	1.8	24
80	Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes, 2016, 65, 585-597.	0.3	136
81	An alternative combination therapy for type 2 diabetes?. Lancet, The, 2015, 385, 2020-2022.	6.3	1
82	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1493-1503.	1.5	13
83	Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. International Journal of Obesity, 2015, 39, 1651-1654.	1.6	41
84	Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes. Diabetes, 2015, 64, 72-78.	0.3	60
85	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. Clinical Investigation, 2014, 4, 729-743.	0.0	3
86	Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2325-E2329.	1.8	104
87	Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care. Clinical Toxicology, 2014, 52, 39-43.	0.8	21
88	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology, 2014, 170, 529-538.	1.9	116
89	Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E418-E426.	1.8	79
90	Glucagon and Type 2 Diabetes: the Return of the Alpha Cell. Current Diabetes Reports, 2014, 14, 555.	1.7	96

#	ARTICLE	IF	CITATIONS
91	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Discovery, 2014, 9, 1223-1251.	2.5	23
92	Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2457-2466.	1.8	31
93	The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. BMJ Open, 2014, 4, e005378-e005378.	0.8	4
94	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia, 2013, 56, 965-972.	2.9	199
95	Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 3346-3352.	4.3	125
96	GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 17-29.	1.5	49
97	Medication review in hospitalised patients to reduce morbidity and mortality. , 2013, , CD008986.		64
98	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, 6, 217.	1.1	37
99	Comment on: Gogebakan et al. Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids. Diabetes 2012;61:292-300. Diabetes, 2012, 61, e12-e12.	0.3	1
100	Add-on to metformin in T2DM—linagliptin or glimepiride?. Nature Reviews Endocrinology, 2012, 8, 576-578.	4.3	0
101	The unobtainable placebo: control of independent clinical research by industry?. Lancet, The, 2012, 379, 30.	6.3	12
102	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ: British Medical Journal, 2012, 344, d7771-d7771.	2.4	731
103	Authors' reply to de Oliveira and Iverson. BMJ: British Medical Journal, 2012, 344, e1459-e1459.	2.4	0
104	Regulation of glucagon secretion by incretins. Diabetes, Obesity and Metabolism, 2011, 13, 89-94.	2.2	132
105	Lixisenatide for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 2011, 20, 549-557.	1.9	70
106	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Review of Endocrinology and Metabolism, 2011, 6, 513-525.	1.2	5
107	Glucose-Dependent Insulinotropic Polypeptide. Diabetes, 2011, 60, 3103-3109.	0.3	265
108	Therapy for Obesity Based on Gastrointestinal Hormones. Review of Diabetic Studies, 2011, 8, 339-347.	0.5	9

#	ARTICLE	IF	CITATIONS
109	The Alpha-Cell as Target for Type 2 Diabetes Therapy. Review of Diabetic Studies, 2011, 8, 369-381.	0.5	49
110	Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?. Current Diabetes Reports, 2010, 10, 124-132.	1.7	42
111	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regulatory Peptides, 2010, 163, 96-101.	1.9	18
112	Prehospital evaluation of patients with chronic obstructive pulmonary disease. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2009, 17, P10.	1.1	0
113	Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs: the Investigational Drugs Journal, 2009, 12, 503-13.	0.7	26
114	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.3	1